Evidence map›Paper›PMID 33688616›Full record

ReviewAPL bioengineering2021

Stimuli-responsive biomaterials for cardiac tissue engineering and dynamic mechanobiology.

Huaiyu Shi, Chenyan Wang, Zhen Ma

Abstract readReview
In one paragraph

Review in APL bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Optically Active, Paper-Based Scaffolds for 3D Cardiac Pacing.ACS applied materials & interfaces · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Can't handle the stress? Mechanobiology and disease.Trends in molecular medicine · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Funding

Establishing an In Vitro Embryotoxicity Risk Classification System Based on Human Cardiac Organoid ModelR01HD101130 · NICHD · SYRACUSE UNIVERSITY · PI MA, ZHEN · 2020 to 2025
$2.3M
In Vitro Model to Study the Role of Microvascular Physiology in Regulation OsteogenesisR21AR076645 · NIAMS · SYRACUSE UNIVERSITY · PI SOMAN, PRANAV · 2020 to 2021
$365k
NIAMS NIH HHS R21 AR076645NICHD NIH HHS R01 HD101130
6 · The paper itself

Abstract

Since the term "smart materials" was put forward in the 1980s, stimuli-responsive biomaterials have been used as powerful tools in tissue engineering, mechanobiology, and clinical applications. For the purpose of myocardial repair and regeneration, stimuli-responsive biomaterials are employed to fabricate hydrogels and nanoparticles for targeted delivery of therapeutic drugs and cells, which have been proved to alleviate disease progression and enhance tissue regeneration. By reproducing the sophisticated and dynamic microenvironment of the native heart, stimuli-responsive biomaterials have also been used to engineer dynamic culture systems to understand how cardiac cells and tissues respond to progressive changes in extracellular microenvironments, enabling the investigation of dynamic cell mechanobiology. Here, we provide an overview of stimuli-responsive biomaterials used in cardiovascular research applications, with a specific focus on cardiac tissue engineering and dynamic cell mechanobiology. We also discuss how these smart materials can be utilized to mimic the dynamic microenvironment during heart development, which might provide an opportunity to reveal the fundamental mechanisms of cardiomyogenesis and cardiac maturation.

Identifiers

PMID33688616
PMCPMC7929620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.